MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Pharmaceuticals, Clinical Trials, CROs, CDMOs & Pharmacovigilance
Biosomilars
Attachments
Information on Biosimilars
Parents
*Driving Forces: Pharmaceuticals, Clinical Trials, CROs, CDMOs & Pharmacovigilance
Children
Biologics are considered to be a major factor in rising healthcare costs - leading to intense interest in biosimilars.
Biosimilar or follow-on biologics are terms used to describe the therapeutics that are highly similar to innovator biopharmaceutical products.
By the year 2020, over $100 billion of biologic products are expected to lose patent protection and many large monoclonal antibodies are coming off patent globally after 2018.
Many of these products are among the highest selling drugs in the world today.
Reference and comparison to the innovator product is an integral component of the approval process.